REACH InsightsDanielle Drayton2026-05-20T17:50:49+00:00

REACH Insights

The Disease-Modifying Era in Angelman Syndrome

February 26th, 2026|

Why Tissue Type Matters Most in the Next Phase of DM1 Therapeutics

February 24th, 2026|

The Unyielding Unmet Need in Huntington’s Disease

February 24th, 2026|

Why IgA Nephropathy Is Entering a New Commercial Phase

February 10th, 2026|

The Disease-Modifying Era in Angelman Syndrome

Amanda Theocles2026-06-10T18:49:00+00:00February 26th, 2026|

Why Tissue Type Matters Most in the Next Phase of DM1 Therapeutics

Amanda Theocles2026-06-10T18:43:44+00:00February 24th, 2026|

The Unyielding Unmet Need in Huntington’s Disease

Amanda Theocles2026-06-10T18:37:06+00:00February 24th, 2026|

Why IgA Nephropathy Is Entering a New Commercial Phase

Danielle Drayton2026-06-09T19:33:58+00:00February 10th, 2026|

Previous 345 Next